127.38
price up icon2.00%   2.50
after-market Dopo l'orario di chiusura: 127.31 -0.07 -0.05%
loading
Precedente Chiudi:
$124.88
Aprire:
$125.06
Volume 24 ore:
792.94K
Relative Volume:
0.57
Capitalizzazione di mercato:
$12.29B
Reddito:
$2.41B
Utile/perdita netta:
$305.80M
Rapporto P/E:
43.18
EPS:
2.95
Flusso di cassa netto:
$492.20M
1 W Prestazione:
+2.59%
1M Prestazione:
+5.26%
6M Prestazione:
-5.96%
1 anno Prestazione:
-2.66%
Intervallo 1D:
Value
$124.86
$127.85
Intervallo di 1 settimana:
Value
$122.66
$127.85
Portata 52W:
Value
$84.23
$157.98

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
Nome
Neurocrine Biosciences Inc
Name
Telefono
(858) 617-7600
Name
Indirizzo
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
Dipendente
1,800
Name
Cinguettio
Name
Prossima data di guadagno
2024-10-30
Name
Ultimi documenti SEC
Name
NBIX's Discussions on Twitter

Confronta NBIX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
127.38 12.29B 2.41B 305.80M 492.20M 2.95
Drug Manufacturers - Specialty & Generic icon
RGC
Regencell Bioscience Holdings Ltd
63.35 303.95B 0 -5.87M -767.30K -0.45
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
155.11 74.39B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.44 48.97B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.90 47.39B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
17.07 20.17B 16.54B -1.64B 749.00M -1.45

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-15 Aggiornamento Needham Hold → Buy
2025-04-14 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2025-02-11 Iniziato Deutsche Bank Hold
2024-10-10 Ripresa Raymond James Outperform
2024-08-29 Aggiornamento Piper Sandler Neutral → Overweight
2024-04-24 Aggiornamento Wells Fargo Equal Weight → Overweight
2023-12-13 Ripresa Citigroup Neutral
2023-12-12 Iniziato Deutsche Bank Buy
2023-10-24 Ripresa Cantor Fitzgerald Overweight
2023-08-21 Reiterato Mizuho Neutral
2023-07-24 Aggiornamento SVB Securities Market Perform → Outperform
2023-07-06 Aggiornamento BMO Capital Markets Underperform → Market Perform
2023-05-04 Aggiornamento Guggenheim Neutral → Buy
2023-03-30 Aggiornamento Canaccord Genuity Hold → Buy
2023-03-03 Aggiornamento Evercore ISI In-line → Outperform
2023-02-03 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2022-11-14 Downgrade Evercore ISI Outperform → In-line
2022-10-11 Iniziato UBS Buy
2022-09-26 Iniziato Wells Fargo Equal Weight
2022-06-06 Ripresa Jefferies Buy
2022-03-03 Downgrade Piper Sandler Overweight → Neutral
2022-02-25 Aggiornamento Goldman Neutral → Buy
2022-01-18 Downgrade RBC Capital Mkts Outperform → Sector Perform
2021-11-19 Iniziato BMO Capital Markets Underperform
2021-11-17 Aggiornamento JP Morgan Neutral → Overweight
2021-10-14 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-09-23 Ripresa Needham Hold
2021-08-06 Downgrade Canaccord Genuity Buy → Hold
2021-05-18 Ripresa Goldman Neutral
2021-05-06 Aggiornamento Barclays Equal Weight → Overweight
2021-02-02 Iniziato Raymond James Outperform
2020-09-30 Iniziato The Benchmark Company Hold
2020-08-04 Downgrade JP Morgan Overweight → Neutral
2020-06-29 Downgrade Goldman Buy → Neutral
2020-06-09 Iniziato Wedbush Outperform
2020-03-06 Iniziato Citigroup Buy
2020-02-27 Iniziato Barclays Equal Weight
2020-02-24 Iniziato William Blair Outperform
2020-02-06 Iniziato Mizuho Neutral
2020-02-05 Reiterato H.C. Wainwright Buy
2019-12-13 Downgrade Credit Suisse Outperform → Neutral
2019-08-07 Iniziato RBC Capital Mkts Outperform
2019-07-16 Iniziato Oppenheimer Outperform
2019-06-05 Iniziato Guggenheim Neutral
2019-05-21 Iniziato Credit Suisse Outperform
2019-04-22 Aggiornamento JP Morgan Neutral → Overweight
2019-04-12 Iniziato Evercore ISI Outperform
2019-02-06 Reiterato BofA/Merrill Buy
2019-01-23 Downgrade JP Morgan Overweight → Neutral
2018-12-13 Iniziato Goldman Buy
2018-11-21 Iniziato Canaccord Genuity Buy
Mostra tutto

Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie

pulisher
Jun 16, 2025

Guggenheim Maintains Buy Rating on Neurocrine Biosciences Following Investor Meeting - MSN

Jun 16, 2025
pulisher
Jun 14, 2025

Neurocrine Biosciences’ SWOT analysis: biotech stock balances Ingrezza success with pipeline potential - Investing.com

Jun 14, 2025
pulisher
Jun 12, 2025

Global Tardive Dyskinesia Treatment Market 2025 | - openPR.com

Jun 12, 2025
pulisher
Jun 11, 2025

Endometriosis Market on Track for Major Expansion by 2034, - openPR.com

Jun 11, 2025
pulisher
Jun 10, 2025

Neurocrine Loses Suit Challenging Hormone Treatment Patent - Law360

Jun 10, 2025
pulisher
Jun 10, 2025

Judge Tosses Neurocrine’s Suit Over Spruce Hormone-Drug Patent - Bloomberg Law News

Jun 10, 2025
pulisher
Jun 09, 2025

Neurocrine Biosciences names new Chief Information Officer By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 09, 2025

Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer - The Malaysian Reserve

Jun 09, 2025
pulisher
Jun 09, 2025

Neurocrine Biosciences (NBIX) Appoints Lewis Choi as CIO | NBIX Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Neurocrine Biosciences Names Lewis Choi as Chief Information Officer - marketscreener.com

Jun 09, 2025
pulisher
Jun 09, 2025

Endometriosis Pain Pipeline 2025: Mechanism of Action, Route - openPR.com

Jun 09, 2025
pulisher
Jun 09, 2025

Neurocrine Biosciences (NBIX) Appoints Lewis Choi as Chief Information Officer - StreetInsider

Jun 09, 2025
pulisher
Jun 09, 2025

Neurocrine Biosciences names new Chief Information Officer - Investing.com

Jun 09, 2025
pulisher
Jun 09, 2025

Former Thermo Fisher AI Chief Joins Neurocrine to Lead Digital Transformation During Product Launch Phase - Stock Titan

Jun 09, 2025
pulisher
Jun 05, 2025

Congenital Adrenal Hyperplasia Market Growth Projections - openPR.com

Jun 05, 2025
pulisher
Jun 03, 2025

(NBIX) Technical Data - news.stocktradersdaily.com

Jun 03, 2025
pulisher
Jun 03, 2025

Nxera earns $15 million as Neurocrine advances schizophrenia drug - The Pharma Letter

Jun 03, 2025
pulisher
Jun 02, 2025

Neurocrine Biosciences Projects Strong Ingrezza Sales For 2025 - Finimize

Jun 02, 2025
pulisher
Jun 02, 2025

Nxera Pharma to Receive US$15 Million from Neurocrine - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568 - GlobeNewswire Inc.

Jun 02, 2025
pulisher
Jun 02, 2025

Analyst Expectations For Neurocrine Biosciences's Future - Benzinga

Jun 02, 2025
pulisher
Jun 02, 2025

Neurocrine Biosciences' Ingrezza to Meet Fiscal 2025 Sales Outlook, RBC Capital Says - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

RBC Capital Reiterates Outperform Rating for Neurocrine Biosciences (NBIX) | NBIX Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Neurocrine Biosciences Announces Phase 4 KINECT-PRO Data - Nasdaq

Jun 02, 2025
pulisher
Jun 02, 2025

[Latest] USA Tardive Dyskinesia Treatment Market: New Drugs, - openPR.com

Jun 02, 2025
pulisher
Jun 02, 2025

Neurocrine (NBIX) Reports Positive Results from INGREZZA Study on Tardive Dyskinesia | NBIX Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Groundbreaking INGREZZA Study Reveals Life-Changing Benefits for Tardive Dyskinesia Patients in Just 4 Weeks - Stock Titan

Jun 02, 2025
pulisher
Jun 01, 2025

Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia - Quantisnow

Jun 01, 2025
pulisher
May 30, 2025

Huntington's Disease Society hosts Team Hope Walk in Tulsa Saturday - KTUL

May 30, 2025
pulisher
May 30, 2025

Director Kevin Gorman Sells 9,613 Shares of Neurocrine Biosciences Inc (NBIX) - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Neurocrine Biosciences, Inc. (NBIX)’s M4 Agonist Shows Promise in Schizophrenia Phase 2 Trial, Phase 3 Launched - MSN

May 30, 2025
pulisher
May 30, 2025

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III - insights.citeline.com

May 30, 2025
pulisher
May 29, 2025

Neurocrine Biosciences director sells shares worth $1.16 million By Investing.com - Investing.com India

May 29, 2025
pulisher
May 29, 2025

Neurocrine Biosciences director sells shares worth $1.16 million - Investing.com

May 29, 2025
pulisher
May 29, 2025

Neurocrine (NBIX) Reports Positive Phase 2 Results for Schizophr - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Taysha’s pivotal trial plans; Keros to stop work on PAH drug, lay off 45% of staff - Endpoints News

May 29, 2025
pulisher
May 29, 2025

Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 - The Malaysian Reserve

May 29, 2025
pulisher
May 28, 2025

Nxera Pharma Notes Neurocrine Biosciences Presents New - GlobeNewswire

May 28, 2025
pulisher
May 28, 2025

Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 - Yahoo Finance

May 28, 2025
pulisher
May 28, 2025

Neurocrine (NBIX) Reports Positive Phase 2 Results for Schizophrenia Treatment | NBIX Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Neurocrine reports positive Phase 2 schizophrenia study results - Investing.com

May 28, 2025
pulisher
May 28, 2025

Neurocrine reports positive Phase 2 schizophrenia study results By Investing.com - Investing.com UK

May 28, 2025
pulisher
May 25, 2025

Neurocrine Biosciences’ SWOT analysis: stock’s resilience amid market challenges - Investing.com Australia

May 25, 2025
pulisher
May 24, 2025

How to Take Advantage of moves in (NBIX) - news.stocktradersdaily.com

May 24, 2025
pulisher
May 23, 2025

Insider Decision Making Waves At Neurocrine Biosciences: CHARLES KEVIN GORMAN Exercises Options, Realizing $0 - Nasdaq

May 23, 2025
pulisher
May 23, 2025

Cetera Investment Advisers Purchases 2,593 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Defense World

May 23, 2025
pulisher
May 20, 2025

Neurocrine at RBC Conference: Growth and Strategic Insights - Investing.com

May 20, 2025
pulisher
May 20, 2025

Transcript : Neurocrine Biosciences, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-20-2025 11 - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

Tourette Syndrome Treatment Market Detailed Analysis - openPR.com

May 20, 2025
pulisher
May 17, 2025

Neurocrine Biosciences (NBIX) Shares Positive Results from Pedia - GuruFocus

May 17, 2025
pulisher
May 16, 2025

Neurocrine reports quality of life gains in tardive dyskinesia study By Investing.com - Investing.com South Africa

May 16, 2025

Neurocrine Biosciences Inc Azioni (NBIX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$291.72
price up icon 1.69%
drug_manufacturers_specialty_generic RDY
$15.19
price down icon 0.39%
$8.77
price up icon 0.11%
$13.32
price down icon 2.13%
$17.07
price up icon 1.10%
Capitalizzazione:     |  Volume (24 ore):